Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic...
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
About this item
Full title
Author / Creator
Iwata, Hiroji , Xu, Binghe , Kim, Sung‐Bae , Chung, Wei‐Pang , Park, Yeon Hee , Kim, Min Hwan , Tseng, Ling‐Ming , Chung, Chi‐Feng , Huang, Chiun‐Sheng , Kim, Jee Hyun , Chiu, Joanne Wing Yan , Yamashita, Toshinari , Li, Wei , Egorov, Anton , Nishijima, Soichiro , Nakatani, Shunsuke , Nishiyama, Yuji , Sugihara, Masahiro , Cortés, Javier and Im, Seock‐Ah
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
The global phase 3 DESTINY‐Breast03 study (ClinicalTrials.gov; NCT03529110) showed statistically significant and clinically meaningful improvements in progression‐free survival (PFS) and overall survival (OS) with trastuzumab deruxtecan (T‐DXd) over trastuzumab emtansine (T‐DM1) in patients with human epidermal growth factor receptor 2 (HER2)‐posit...
Alternative Titles
Full title
Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2‐positive metastatic breast cancer
Authors, Artists and Contributors
Author / Creator
Xu, Binghe
Kim, Sung‐Bae
Chung, Wei‐Pang
Park, Yeon Hee
Kim, Min Hwan
Tseng, Ling‐Ming
Chung, Chi‐Feng
Huang, Chiun‐Sheng
Kim, Jee Hyun
Chiu, Joanne Wing Yan
Yamashita, Toshinari
Li, Wei
Egorov, Anton
Nishijima, Soichiro
Nakatani, Shunsuke
Nishiyama, Yuji
Sugihara, Masahiro
Cortés, Javier
Im, Seock‐Ah
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11462951
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11462951
Other Identifiers
ISSN
1347-9032,1349-7006
E-ISSN
1349-7006
DOI
10.1111/cas.16234
